Advertisement
UK markets closed
  • NIKKEI 225

    39,239.52
    +5.81 (+0.01%)
     
  • HANG SENG

    16,790.80
    +156.06 (+0.94%)
     
  • CRUDE OIL

    78.41
    +0.83 (+1.07%)
     
  • GOLD FUTURES

    2,039.80
    +0.90 (+0.04%)
     
  • DOW

    38,905.41
    -163.82 (-0.42%)
     
  • Bitcoin GBP

    44,888.25
    +2,839.74 (+6.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,980.70
    +4.45 (+0.03%)
     
  • UK FTSE All Share

    4,191.43
    +0.63 (+0.02%)
     

The Global Bronchodilators Market size is expected to reach $27 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period

ReportLinker
ReportLinker

Bronchodilators are drugs that relax the muscles which tighten around the airways. These drugs open airways and allow more air to come and pass through the lungs and decrease mucus from the lungs.

New York, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06422825/?utm_source=GNW
Patients suffering from various respiratory disorders take these drugs through nebulizers or inhalers. Also, inhaling bronchodilators have effects on mucociliary clearance too.

Bronchodilators are also utilized to treat obstructive lung diseases by relaxing the muscles in the lungs and widening the airways (bronchi). They also treat chronic obstructive pulmonary diseases (COPD) and asthma. The relaxation of the muscles in the airways due to the bronchodilators, opens them up and the bronchial tube to widen. They come in different types and each works in a slightly different way than the other. They are; beta 2-agonists, anticholinergics and xanthine derivatives (theophylline).

Beta-2 agonists are utilized for both COPD and asthma, but some beta-2 agonists are only recommended for patients with COPD. They are generally inhaled with the help of a small handheld inhaler but are available as syrups or tablets too. In case of sudden or severe symptoms, they can also be injected into the body or nebulized. A nebulizer is a compressor that changes the liquid medication into a fine mist. Beta-2 agonists work by stimulating receptors known as beta-2 receptors in the muscles that are in the airways, which causes them to relax and allow the airways to dilate.

Anticholinergics, also known as antimuscarinics, are majorly used for treating COPD, but in some cases, they can also be used to treat asthma. They are taken with the help of an inhaler, but nebulizing the medication is also available for sudden need. Anticholinergics cause the airway to dilate by blocking the cholinergic nerves. These nerves release a chemical that can force the muscles lining the airways to tighten up. Theophylline is generally taken in capsule or tablet form, but a different version called aminophylline can be given directly into the vein if the symptoms are severe.

COVID-19 Impact Analysis

COVID-19 has impacted the bronchodilators market in the starting phase due to the lockdowns by many nations with the denied COPD and asthma treatment due to the given importance to COVID-19 patients. Because of the halt in the supply chain, there was a shortage of bronchodilator medications. Many bronchodilators manufacturing companies were forced to stop their production due to the pandemic and labor shortage. Furthermore, business operations were halted due to the new government regulations, which directly influenced the companies’ revenue in the bronchodilators market.

Market Growth Factor

Increasing air pollution across the globe

Motor vehicles, household combustion, forest fires, and industrial facilities are familiar air pollution sources. Pollutants of primary public health concern contain particulate matter, carbon monoxide, ozone, sulfur dioxide, and nitrogen. Indoor and outdoor air pollution cause respiratory and other diseases and are significant factors for mortality and morbidity. According to World Health Organization, almost all of the world’s population breathes air that exceeds WHO guideline limits and has high levels of pollutants. Out of that, low and middle-income countries are suffering from the highest exposures.

Surging number of geriatric populations

According to WHO, one in every six people in the world will be aged 60 years or over by 2030. The share of the world’s population aged 60 years and above will rise from 1 billion in 2020 to 1.4 billion. The world’s population of people aged 60 years and older will double to around 2.1 billion, and the 80 years old will triple to 426 million between 2020 and 2050. While this shift in the distribution of a country’s population towards the older ages, called population aging, has already started in high-income nations, it is now experiencing the most significant change in low- and middle-income countries. By 2050, two-thirds of the world’s population will be over 60 years old and in low- or middle-income countries.

Market Restraining Factor

High cost of imaging equipment

A chest X-ray can aid in assisting the diagnosis of many lung diseases and rule out other causes of shortness of breath. Various hospitals in developing nations cannot invest in diagnostic imaging equipment due to high costs and financial restrictions. Many hospitals that cannot buy new cutting-edge imaging systems instead opt to utilize rebuilt imaging systems because of the high demand for diagnostics procedures, especially in low-income countries.

Drug Class Outlook

Based on drug class, the bronchodilators market is segmented into beta-adrenergic, xanthine derivatives and anticholinergic. The anticholinergic segment acquired a promising growth rate in the bronchodilators market in 2021. This is due to anticholinergics’ availability in short- and long-acting formulations. These drugs prevent the parasympathetic nerve reflexes from airways constriction, which allows the airways to remain open.

Route of Administration Outlook

On the basis of route of administration, the bronchodilators market is divided into oral, nasal (inhalable) and injectable. The oral segment procured a prominent revenue share in the bronchodilator market in 2021. This is because many patients and clinicians prefer to avoid the adverse effects of injectables administration. Also, they are less costly than many generic substitutes and have many advantages like non-invasiveness, the convenience of drug administration, and patient compliance.

Disease Outlook

By disease, the bronchodilators market is classified into asthma, chronic obstructive pulmonary disease (COPD) and others. The asthma segment witnessed the largest revenue share in the bronchodilator market in 2021. This is due to the rising prevalence of asthma among the population. In addition, there is a robust research and development pipeline with many mid or late-stage development organizations.

Regional Outlook

Region-wise, the bronchodilators market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the bronchodilator market in 2021. The growth is due to the increasing demand for fast-acting and high-efficiency drugs. The surging COPD cases are due to air pollution, dust, working with chemicals, a history of childhood lung infection, and second-hand smoke. Also, there is a large number of smokers who are suffering from a smoke-related disease. The air pollution, high smoker count, and the rising number of old adults are expected to boost the bronchodilators market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

• Beta-Adrenergic

• Xanthine Derivatives

• Anticholinergic

By Route of Administration

• Nasal (Inhalable)

• Oral

• Injectable

By Disease

• Asthma

• Chronic Obstructive Pulmonary Disease (COPD)

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Glenmark Pharmaceuticals Limited

• Merck & Co., Inc.

• GlaxoSmithKline PLC

• AstraZeneca PLC

• Teva Pharmaceuticals Industries Ltd.

• Cipla Limited

• Viatris, Inc.

• Novartis AG

• Boehringer Ingelheim International GmbH

• Sun Pharmaceutical Industries Ltd.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06422825/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001